Crude Oil Falls Sharply; Dell Shares Spike Higher - Apogee Therapeutics (NASDAQ:APGE), Atlantic International (NASDAQ:ATLN) Dow up 2.45%, Nasdaq up 2.46%, S&P; 500 up 2.19%. Consumer discretionary shares up 3.6%, energy stocks up 0.3%. Dell announces enhancements, BofA raises price target. Apogee up 17%, Tower Semi up 9%, Urban-gro up 46%. Atlantic Int'l down 13%, Linkers down 85%, Valneva down 37%. Oil down 8.1%, gold down 2.1%. European and Asian markets mixed.

Crude Oil Falls Sharply; Dell Shares Spike Higher Dow up 2.45%, Nasdaq up 2.46%, S&P 500 up 2.19%. Consumer discretionary shares up 3.6%, energy stocks up 0.3%. Dell announces enhancements, Bof...

#APGE #ATLN #DELL #Equities #LNKS #Mid-Day #Market #Update #News #PFE #TSEM

Origin | Interest | Match

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial Pfizer (NYSE: PFE) and Valneva reported Phase 3 VALOR results for investigational Lyme vaccine PF-07307405 (LB6V), showing ~73–75% efficacy versus placebo in pre-specified analyses. The candidate was well tolerated with no safety concerns identified at analysis. Fewer-than-expected cases limited statistical power; Pfizer plans regulatory submissions.Key metrics: efficacy 73.2% (28 days post-dose 4) and 74.8% (1 day post-dose 4), with wide 95% CIs. Collaboration grants Pfizer exclusive manufacturing and commercialization rights upon approval.

#PFE #VALN Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

www.stocktitan.net/news/PFE/pfizer-and-valn...

Pfizer says investors risk a below-market price in $32 share offer The unsolicited bid targets 1M shares, about 0.02% outstanding, and expires April 13. Pfizer says Tutanota lacks financing and holders can withdraw.

#PFE Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

www.stocktitan.net/news/PFE/pfizer-recommen...

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer Pfizer (NYSE: PFE) reported positive topline Phase 3 TALAPRO-3 results: TALZENNA plus XTANDI met the primary endpoint with a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) versus placebo plus XTANDI, exceeding the pre-specified hazard ratio target of 0.63.Consistent benefit was seen in BRCA and non-BRCA HRR gene–mutated metastatic castration-sensitive prostate cancer; an interim analysis showed a strong trend toward improved overall survival. Results will be presented and discussed with global health authorities.

#PFE TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

www.stocktitan.net/news/PFE/talzenna-plus-x...

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer Pfizer (NYSE: PFE) reported positive topline Phase 2 FOURLIGHT-1 results for atirmociclib in HR+, HER2- metastatic breast cancer, meeting the primary endpoint with a 40% reduction in risk of progression or death (HR 0.60; 95% CI 0.440–0.825; p=0.0007).Results were consistent across prespecified subgroups, >90% of patients started atirmociclib within three months of prior CDK4/6 inhibitor therapy, overall survival was immature (~20% events), and safety was manageable with 6.4% discontinuations due to adverse events. Phase 3 first-line study is ongoing.

#PFE Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

www.stocktitan.net/news/PFE/pfizer-announce...

Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis Pfizer (NYSE: PFE) reported positive topline Phase 2 results for tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis, meeting the primary endpoint with statistically significant EASI-75 improvements at Week 16 across doses.Placebo-adjusted EASI-75 at Week 16: 38.7% (low), 51.9% (middle), 49.4% (high). Pfizer plans Phase 3 initiation this year and will present detailed results at future medical meetings.

#PFE Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

www.stocktitan.net/news/PFE/pfizer-s-phase-...

#AMRN #PFE #0089231e-89c6-4d30-afb1-1c791257fbca #investing #Health #Care

Origin | Interest | Match

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#TSM, #AMPX, #OXY, #NBIS, #PFE

#OptionFlow #OptionsTrading #Trading

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#TECK, #CORZ, #HON, #BA, #PFE

#OptionFlow #OptionsTrading #Trading

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer Pfizer (NYSE: PFE) and Astellas announced Phase 3 EV-304 results showing perioperative PADCEV plus Keytruda cut risk of recurrence/progression or death by 47% versus neoadjuvant gemcitabine+ciplatin (HR 0.53; 95% CI 0.41–0.70; 1-sided p<.0001).Two‑year event‑free survival was estimated at 79.4% versus 66.2%; overall survival improved (HR 0.65; 95% CI 0.48–0.89; 1-sided p=0.0029) and pathological complete response reached 55.8% versus 32.5% at surgery.

#PFE PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

www.stocktitan.net/news/PFE/padcevtm-keytru...

$BCE www.bce.ca/investors/ov...
$UBER investor.uber.com/home/default...
$IYT Ishares Transportation ETF
$NKE investors.nike.com/Home/default...
#PFE investors.pfizer.com/Investors/Ov...
$LMND www.lemonade.com/investor
$RIVN rivian.com/en-CA/invest...
$RKT ir.rocketcompanies.com/home/default...

Here is my updated stock portfolio.

$BCE
$UBER
$IYT Ishares Transportation ETF
$NKE
#PFE
$LMND
$RIVN
$RKT

European Parliament Tries to Bury the Right to Seek Asylum The European Parliament voted today to usher in changes to European Union asylum rules that jeopardize the right to seek asylum.

The EU Parliament's #VenezuelaMajority (the centre-right #EPP & the #farright groups #PfE, #ECR, & #ESN) was at it again yesterday.
The topic? #Migration, "safe third countries", & “safe countries of origin” lists.
A core tenet of #asylum policy, decided by the far-right.
www.hrw.org/news/2026/02...

Today’s most trending tickers with positive sentiment (last 24h):

#GOOGL: 38
#AMD: 31
#SPY: 20
#GOOG: 17
#LLY: 15
#SMCI: 15
#MSFT: 15
#PLTR: 12
#NXXT: 10
#IGV: 9
#ASTS: 9
#AAPL: 9
#TSLA: 9
#YUM: 8
#BTC: 8
#PFE: 8
#ELF: 8
#PEP: 7

#PFE makes waves with positive results from GLP-1 trial and strong quarterly earnings, reaffirming growth potential.

Today’s most trending tickers with positive sentiment (last 24h):

#PLTR: 46
#SPY: 31
#AMD: 30
#PFE: 17
#DIS: 16
#MSFT: 15
#TSLA: 14
#PYPL: 14
#SMCI: 13
#WMT: 12
#PEP: 12
#LIMN: 10
#AAPL: 8
#GME: 8
#HOOD: 8
#PSQH: 7
#USAR: 7
#BTC: 7

📈 Heavy institution #Equity #optionsvolume! AM Top Equity Activity from 🔥 INSIDERFINANCE.COM 🔥 1

📈 Heavy institution #Equity #optionsvolume!

AM Top Equity Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #NVDA 208.9K
2. #AAPL 42.8K
3. #TSLA 36.0K
4. #PFE 33.1K
5. #CLSK 28.7K

#OptionFlow #OptionsTrading #Trading

💥 Institutions trading #options with high urgency! AM Top Sweep Activity from 🔥 INSIDERFINANCE.CO

💥 Institutions trading #options with high urgency!

AM Top Sweep Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #NVDA 187.6K
2. #AAPL 40.5K
3. #PFE 31.8K
4. #PLTR 27.3K
5. #TSLA 27.2K

#OptionFlow #OptionsTrading #Trading

📢 Stocks Trending NOW: #PYPL #PFE #PLTR #CAT #PEP #MRK #FUBO #TER #NPT #ETN

after earnings:

#PEP Pepsico = -0.5%
#MRK Merck = -0.5%
#PFE Pfizer = -3%
#PYPL PayPal = -16%

#PFE PFIZER
Q4 REVENUE USD 17,557 MILLION VS ESTIMATE USD 16,950 MILLION
Q4 ADJUSTED EPS USD 0.66 VS ESTIMATE USD 0.57

💥 Institutions trading #options with high urgency! PM Top Sweep Activity from 🔥 INSIDERFINANCE.CO

💥 Institutions trading #options with high urgency!

PM Top Sweep Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #NVDA 98.1K
2. #UNH 66.6K
3. #BA 59.8K
4. #AMZN 50.5K
5. #PFE 45.9K

#OptionFlow #OptionsTrading #Trading

💥 Institutions trading #options with high urgency! AM Top Sweep Activity from 🔥 INSIDERFINANCE.CO

💥 Institutions trading #options with high urgency!

AM Top Sweep Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #NVDA 50.6K
2. #UNH 49.9K
3. #PFE 29.8K
4. #CRWV 19.6K
5. #AAPL 18.5K

#OptionFlow #OptionsTrading #Trading

📈 Heavy institution #Equity #optionsvolume! AM Top Equity Activity from 🔥 INSIDERFINANCE.COM 🔥 1

📈 Heavy institution #Equity #optionsvolume!

AM Top Equity Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #NVDA 63.4K
2. #UNH 53.1K
3. #CRWV 35.3K
4. #PFE 29.8K
5. #AAPL 18.5K

#OptionFlow #OptionsTrading #Trading

Pfizer Inc (PFE) 3bil added to market cap in 1 hour #PFE #Pfizer

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#PFE, #ARBE, #EBAY, #MOS, #LMND

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #PFE 28.6x
2. #ARBE 22.9x
3. #EBAY 13.0x
4. #MOS 9.7x
5. #LMND 8.1x

#OptionFlow #OptionsTrading #Trading

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ARBE, #BABA, #CRML, #PFE, #SIDU

#OptionFlow #OptionsTrading #Trading

#PFE Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug Viagra in 1998, CEO Albert Bourla said

#TEM #LLY #PFE #NVO #208956d4-2149-4d90-8144-5317dd54ac0c #investing #Health #Care

Origin | Interest | Match